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796Background: Efforts to reduce blood product use have the potential to avoid transfusion-related complications
and reduce health care costs. The purpose of this investigation was to determine whether a multi-institutional
effort to reduce blood product use affects postoperative events after cardiac surgical operations and to determine
the influence of perioperative transfusion on risk-adjusted outcomes.
Methods: A total of 14,259 patients (2006-2010) undergoing nonemergency, primary, isolated coronary artery
bypass grafting operations at 17 different statewide cardiac centers were stratified according to transfusion guide-
line era: pre-guideline (n¼ 7059, age¼ 63.7 10.6 years) versus post-guideline (n¼ 7200, age¼ 63.7 10.5
years). Primary outcomes of interest were observed differences in postoperative events and mortality risk-
adjusted associations as estimated by multiple regression analysis.
Results:Overall intraoperative (24% vs 18%, P<.001) and postoperative (39% vs 33%, P<.001) blood prod-
uct transfusion were significantly reduced in the post-guideline era. Patients in the post-guideline era demon-
strated reduced morbidity with decreased pneumonia (P ¼ .01), prolonged ventilation (P ¼ .05), renal failure
(P¼ .03), new-onset hemodialysis (P¼ .004), and composite incidence of major complications (P¼ .001). Op-
erative mortality (1.0% vs 1.8%, P<.001) and postoperative ventilation time (22 vs 26 hours, P<.001) were
similarly reduced in the post-guideline era. Of note, after mortality risk adjustment, operations performed in the
post-guideline era were associated with a 47% reduction in the odds of death (adjusted odds ratio, 0.57;
P<.001), whereas the risk of major complications andmortality were significantly increased after intraoperative
(adjusted odds ratio, 1.86 and 1.25; both P<.001) and postoperative (adjusted odds ratio, 4.61 and 4.50, both
P<.001) transfusion. Intraoperative and postoperative transfusions were associated with increased adjusted in-
cremental total hospitalization costs ($4408 and $10,479, respectively).
Conclusions: Implementation of a blood use initiative significantly improves postoperative morbidity, mortal-
ity, and resource utilization. Limiting intraoperative and postoperative blood product transfusion decreases ad-
verse postoperative events and reduces health care costs. Blood conservation efforts are bolstered by
collaboration and guideline development. (J Thorac Cardiovasc Surg 2013;145:796-804)Perioperative anemia is associated with increasedmorbidity
and mortality among patients undergoing cardiac surgery,
and accumulated evidence has demonstrated that allogenic
blood product transfusion is an effective method of treating
anemia.1-5 However, conflicting data have demonstrated
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The Journal of Thoracic and Cardiovascular Surggreater postoperative complications, including nosocomial
infections, immunosuppression, transfusion-related acute
lung injury, decreased health-related quality of life, and re-
duced early and long-term survival.6-18 As a result, efforts to
reduce blood product use have the potential to avoid
transfusion-related complications and to reduce health
care costs. To date, many series investigating strategic ap-
proaches to blood conservation in cardiac surgery are lim-
ited by single institutional experiences.11,19-23 Few studies
have investigated the economic considerations of blood
transfusion-related costs and the potential cost-savings of
a successful blood conservation initiative.
The Virginia Cardiac Surgery Quality Initiative (VCSQI)
is a voluntary consortium of 17 different collaborating car-
diac surgical centers, both academic and private, within the
Commonwealth of Virginia. This group exchanges and
compares deidentified patient data on a quarterly basis in
an effort to improve cardiac surgical care, quality, and costs.ery c March 2013
Abbreviations and Acronyms
AOR ¼ adjusted odds ratio
AUC ¼ area under the receiver operating
characteristic curve
CABG ¼ coronary artery bypass grafting
HGLM ¼ hierarchic general linear model
PRBC ¼ packed red blood cell
PROM ¼ predicted risk of mortality
SCIP ¼ Surgical Care Improvement
STS ¼ Society of Thoracic Surgeons
VCSQI ¼ Virginia Cardiac Surgery Quality
Initiative
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quality-improvement opportunities in cases in which
high-cost, resource-intensive, or frequently occurring pre-
ventable outcomes might occur. Collectively, the VCSQI
centers perform approximately 99% of the Common-
wealth’s cardiac operations, and each center individually
contributes patient data to the national Society of Thoracic
Surgeons (STS) Adult Cardiac Surgery Database.
The purpose of this study was (1) to determine whether
a multi-institutional effort to reduce blood product transfu-
sion could be successfully implemented and achieved, and
(2) to assess the impact of established transfusion guide-
lines on postoperative events after cardiac surgical opera-
tions and the influence of intraoperative and postoperative
blood product transfusion on risk-adjusted outcomes. We
hypothesized that successful implementation of blood prod-
uct transfusion guidelines would result in a significant re-
duction in intraoperative and postoperative blood product
transfusion and improve patient outcomes.
MATERIALS AND METHODS
This investigation was exempt from formal institutional review board
review at each participating center because it represents a secondary anal-
ysis of the VCSQI data registry with the absence of Health Insurance Por-
tability and Accountability Act patient identifiers and because the data are
collected for quality analysis and purposes other than research.
Patients and Data Acquisition
Deidentified patient-level data were obtained from the VCSQI data-
base for the study period August 1, 2006, to June 30, 2010. All records
included patients undergoing nonemergency, isolated, primary coronary
artery bypass grafting (CABG) operations (STS procedure type ‘‘CAB
Only’’). Patient records were stratified according to transfusion guideline
era: pre-guideline era (August 1, 2008, to July 31, 2008) and post-
guideline era (August 1, 2008, to July, 31, 2010). Emergency CABG
cases were excluded. All CABG procedures represent standard surgical
approaches to surgical myocardial revascularization with and without
the use of cardiopulmonary bypass support, and standard STS variable
definitions were used.24 Patient preoperative risk was assessed by preva-
lence of patient comorbid disease, extent of coronary artery disease, op-
erative status, and individual calculated STS predicted risk of mortality
(PROM).The Journal of Thoracic and CaBlood Product Use Protocol
The potential clinical and financial benefits that could be achieved
through a coordinated blood conservation initiative represents one of the
leading efforts by theVCSQI since early 2008.AmongVCSQI participants,
consensus agreement was achieved to establish a blood conservation initia-
tivewith blood product transfusion guidelines to be implemented for a con-
secutive 2-year period beginning in August 2008. The adopted transfusion
guidelines included both intraoperative and postoperative transfusion
thresholds and practices of care. Intraoperative transfusion triggers included
packed red blood cell (PRBC) transfusion for hemoglobin levels less than
6.0 g/dL or a hematocrit level less than 18%while on cardiopulmonary by-
pass in addition to one of the following: (1) low oxygen saturation (<60mm
Hg), (2) elevated lactate level (>2.2mmol/L), (3) elevated base deficit (base
deficit>3mEq/L), or (4) low serumbicarbonate level (<22mEq/L). Similar
postoperative transfusion triggers also were established to include PRBC
transfusion for hemoglobin levels less than 7.0 g/dL or hematocrit level
less than 21% in addition to at least one of the following clinical criteria:
(1) elevated oxygen requirement, (2) systemic hypotension, (3) evidence
of end-organ dysfunction, or (4) evidence of persistent bleeding.
Measured Outcomes
The primary outcomes of interest included risk-adjusted associations
between mortality and morbidity and transfusion guideline era, and in-
traoperative and postoperative blood product transfusion. Secondary out-
comes included estimated risk-adjusted correlations between
intraoperative and postoperative blood product transfusion and total costs
and observed differences in the incidence of postoperative events. Opera-
tive mortality was defined as all patient deaths occurring during hospitali-
zation and those within 30 days of the date of surgery despite discharge
status. A composite outcome of major complications was used as a proxy
for major morbidity and included the incidence of deep sternal wound in-
fection, postoperative stroke, renal failure, prolonged ventilation, pneumo-
nia, and need for reoperation. Standard STS definitions for postoperative
events and complications were used, including prolonged ventilation
(>24 hours of mechanical ventilation), presence of any new-onset atrial fi-
brillation, and renal failure (increase in serum creatinine level>2.0 or
a doubling [23] of the most recent preoperative creatinine level).24
Cost Data and Acquisition
VCSQI uses an information system that combines standardized clinical
data extracted from STS data-entry forms with hospital inpatient discharge
financial data. Hospital inpatient data from UB-92 and UB-04 files are
matched with each STS patient record. The patient data involve inpatient
hospital stays exclusively for cardiac surgical operations. The UB-92 and
UB-04 file contains the final bill (not cyclic or interim bills) and the pa-
tient’s date of discharge, and is accompanied by a charge detail file and
a physician file. Considering that the UB-92 and UB-04 records contain
patient charge data, the VCSQI developed a 2-step procedure making the
financial data more comparable from one provider organization to another.
First, all of the International Classification of Diseases, 9th Revision–based
revenue codes contained in the patient records are aggregated and sorted
into 21 different cost categories. Second, a set of cost-to-charge ratios is
submitted from each provider organization and multiplied by each of the
21 cost categories. The product is a set of normalized charges that are ap-
proximately comparable from one surgeon and provider to another. When
the normalized charges are summed over the 21 cost categories, an estimate
of the total cost of that inpatient stay is derived. The VCSQI maintains
a 99% matching rate between STS patient records and billing data.
Statistical Analysis
All statistical analyses were designed to test the null hypotheses that pa-
tient outcomes would not significantly differ as a function of transfusion
guideline era or the presence of intraoperative/postoperative blood productrdiovascular Surgery c Volume 145, Number 3 797
TABLE 1. Descriptive statistics for patients undergoing coronary
artery bypass grafting by transfusion guideline era
Variable
Pre-guideline
era (n ¼ 7059)
Post-guideline
era (n ¼ 7200) P
Age (y)* 63.7  10.6 63.7  10.5 .97
Sex (female) 26.0% 26.0% .37
Hypertension 81.7% 85.1% <.001
Diabetes 39.8% 39.8% .97
Dyslipidemia 72.2% 71.4% .30
Atrial fibrillation 3.7% 4.1% .22
PVD 13.5% 13.0% .42
NYHA class .02
I 7.6% 5.1%
II 35.3% 34.2%
III 42.5% 43.7%
IV 14.5% 17.0%
Renal failure 4.0% 3.1% <.001
Cardiac presentation on
admission
<.001
No symptoms or angina 9.4% 9.1%
Stable angina 26.2% 26.7%
Unstable angina 34.6% 35.3%
ST-elevation MI 6.3% 6.0%
Non–ST-elevation MI 21.0% 20.8%
Prior PCI 21.4% 23.3% .008
Left main>50% 30.5% 29.6% .21
Preoperative ASA 83.0% 87.3% <.001
Antiplatelet within 5 d 1.6% 4.2% <.001
STS PROM (%)y 0.9% (0.6-1.8) 0.8% (0.4-1.6) <.001
PVD, Peripheral vascular disease; NYHA, New York Heart Association;MI, myocar-
dial infarction; PCI, percutaneous coronary intervention; ASA, acetylsalicylic acid;
STS, Society of Thoracic Surgeons; PROM, predicted risk of mortality; ST, segment.
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Mtransfusion. Study outcomes and data comparisons were established a priori
before data collection. Categoric variables are expressed as standard group
percentages, and continuous variables are expressed asmean standard de-
viation or median (25th, 75th percentile) depending on overall variable dis-
tribution. Descriptive, univariate statistics included Pearson’s chi-square or
Fisher exact test for categoric variables and the independent sample single
factor analysis of variance for comparisons of normally distributed data or
the Mann–Whitney U test for non-normally distributed data comparisons.
Calculated test statistics were used to derive all 2-tailed P values.
Hierarchic multiple logistic regression models were used to estimate
confounder-adjusted associations between intraoperative and postoperative
blood product transfusion, and transfusion guideline era and observed pa-
tient morbidity (major complications) and operative mortality. To account
for inter-hospital variance in correlated events, clustering at the hospital
level was considered in the hierarchic structure of each logistic regression
model. Model covariates were selected a priori on the basis of established
clinical risk or considered potential confounders for the influence of blood
product protocol implementation on patient outcomes. Performed models
were adjusted for baseline patient risk by inclusion of the calculated STS
PROM score, individual surgeon influence on patient outcomes and trans-
fusion behavior by inclusion of surgeon identification, influence of baseline
changes in practice over the study period by inclusion of the operative/
transfusion era, and intraoperative and postoperative blood product trans-
fusion. In addition, a hierarchic general linear model (HGLM) was used
to assess the risk-adjusted influence of intraoperative and postoperative
blood product transfusion on total costs, adjusting for the same model co-
variates. Confounder-adjusted measures of association are reported as odds
ratios with a 95% confidence interval for all logistic regression models and
the unstandardized ß with a 95% confidence interval for HGLM results.
Model performance was assessed using the area under the receiver operat-
ing characteristic curve (AUC), and the Hosmer–Lemeshow test was used
to verify model calibration across deciles of observed and predicted risk.
Predictive Analytics SoftWare (PASW) with complex sampling module
software, version 18.0.0 (IBMCorp, Somers, NY) was used for all data ma-
nipulation and statistical analyses.*Results reported as mean  standard deviation. yResults reported as median (25th-
75th percentile).RESULTS
Patient Characteristics and Operative Features for
Coronary Artery Bypass Grafting
Table 1 reports patient characteristics and operative fea-
tures for all patients undergoing CABG operations stratified
by blood product transfusion guideline era. A total of 7059
patients (49.5%) underwent CABG during the pre-
guideline era (August 2006 to July 2008), and 7200 patients
(50.5%) underwent CABG during the post-guideline era
(August 2008 to July 2010). The average patient age was
63 years in both surgical eras, and gender distribution was
the same. With respect to major cardiovascular comorbid-
ities, small differences were prevalent between patient co-
horts. Patients in the pre-guideline era presented with
slightly lower percentage of New York Heart Association
class III and IV functional status, slightly higher percentage
of preoperative renal failure, and lower percentage of prior
percutaneous coronary interventions. Small differences in
the type of cardiac presentation of admission existed be-
tween groups. The presence of significant left main coro-
nary disease was approximately 30% in each patient
cohort. Patients in the post-guideline era presented with
a higher percentage of preoperative aspirin (acetylsalicylic798 The Journal of Thoracic and Cardiovascular Surgacid) use and antiplatelet therapy (clopidogrel) within 5
days of surgery compared with those in the pre-guideline
era. Ultimately, these differences translated into minor dif-
ferences in preoperative risk as assessed by calculated STS
PROM scores, with patients in the pre-guideline era pre-
senting with median PROM scores of 0.9% compared
with 0.8% for those in the post-guideline era (P<.001).
Table 2 displays the operative details for patients under-
going CABG in both pre- and post-guideline eras. The large
majority of operations were performed with the use of car-
diopulmonary bypass support (91%), with approximately
9% performed off-pump. Patients in the pre-guideline era
underwent a higher percentage of elective operations, and
patients in the post-guideline era underwent more urgent
operations. The majority of revascularizations included
use of the left internal thoracic artery and a single saphenous
vein graft.
Comparison of Blood Product Transfusion Rates by
Guideline Era
The incidence of intraoperative and postoperative blood
product transfusion, and differences in transfused productsery c March 2013
TABLE 2. Operative features of patients undergoing coronary artery
bypass grafting procedures by transfusion guideline era
Outcome
Pre-guideline
era (n ¼ 7059)
Post-guideline
era (n ¼ 7200) P
CPB 92.5% 90.6% <.001
Elective status 48.2% 37.7% <.001
Urgent status 51.8% 62.7% <.001
SVG <.001
1 SVG 85.2% 84.8%
2 SVG 8.6% 8.9%
3 SVG 1.6% 2.0%
4 SVGs 0.3% 0.7%
LITA 91.3% 93.2% <.001
RITA 0.3% 0.4%
BITA 4.0% 2.7%
CPB, Cardiopulmonary bypass; SVG, saphenous vein graft; LITA, left internal tho-
racic artery; RITA, right internal thoracic artery; BITA, bilateral internal thoracic
artery.
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Overall, significant decreases in the rate of both intraopera-
tive and postoperative transfusionwere observed in the post-
guideline era. Intraoperative transfusion rates decreased by
7% (24% vs 17%, P<.001) in the post-guideline era. Like-
wise, postoperative transfusion rates decreased by 6% (39%
vs 33%, P<.001) in the post-guideline era. With respect to
specific blood components, the average number of total
transfused intraoperative products and intraoperative
PRBC units significantly decreased in the post-guideline
era. Of note, a significant reduction in the average number
of postoperative transfusions (total units, PRBC units,
fresh-frozen plasma units, and platelet units) also was ob-
served in the post-guideline era.
Comparisons of Unadjusted Incidence of
Postoperative Events as Function of Transfusion
Guideline Era
Significant improvement in the unadjusted incidence of
postoperative morbidity and mortality was observed duringTABLE 3. Comparison of blood product use by transfusion guideline
era
Outcome
Pre-guideline
era (n ¼ 7059)
Post-guideline
era (n ¼ 7200) P
Intraoperative transfusion 24.0% 17.7% <.001
Total products (U)* 0.6  1.8 0.1  1.5 <.001
PRBC (U)* 0.4  0.8 0.2  0.8 <.001
FFP (U)* 0.1  0.2 0.1  0.3 .30
Platelet (U)* 0.2  1.0 0.1  0.6 .07
Postoperative transfusion 39.1% 32.8% <.001
Total products (U)* 1.4  3.8 0.4  1.9 <.001
PRBC (U)* 0.9  2.0 0.7  1.9 <.001
FFP (U)* 0.2  0.9 0.1  1.1 <.001
Platelet (U)* 0.2  1.2 0.1  0.6 <.001
PRBC, Packed red blood cells; FFP, fresh-frozen plasma. *Results reported as
mean  standard deviation.
The Journal of Thoracic and Cathe post-guideline era (Table 4). Although statistically
shorter in the post-guideline era, median cardiopulmonary
bypass times were clinically similar during both transfusion
eras. With respect to postoperative morbidity, patients in the
post-guideline era incurred lower composite major com-
plication rates (13% vs 15%, P< .001) with decreased
incidence of pneumonia, prolonged ventilation, renal fa-
ilure, and new-onset hemodialysis requirements. Post-
operative ventilation time was similarly reduced in the
post-guideline era. Blood conservation also resulted in
a significant decrease in operative mortality during the
post-guideline era (1.0%) compared with pre-guideline
era mortality (1.8%, P<.001). Despite similar postopera-
tive hospital durations (median, 5 days), patients in the
post-guideline era accrued significantly lower total costs
than patients in the pre-guideline era. Overall total hospital-
ization costs for the patients in the pre-guideline era was
$261 million compared with $212 million for patients in
the post-guideline era, providing for a net decrease in total
costs of $49 million (P<.001). Likewise, a median reduc-
tion of approximately $4000 per patient hospitalization
(P < .001) was observed during the post-guideline era.
These cost-savings were largely driven by reductions in in-
tensive care unit/cardiac care unit costs (P<.0001) and re-
spiratory therapy costs (P< .0001) among patients in the
post-guideline era.
Results of Risk-Adjusted Models
Because of differences in patient risk profiles, risk-
adjusted associations between transfusion guideline era
and as intraoperative and postoperative blood product trans-
fusions and patient morbidity and mortality were estimated
using hierarchic multiple regression models (Table 5). After
adjusting for the influence of hospital variability and patient
risk, using the calculated STS PROM, CABG operations
performed in the post-guideline era were associated with
a 47% reduction in the odds of mortality (adjusted odds
ratio [AOR], 0.53; P<.001) compared with operations per-
formed in the pre-guideline era. On estimating the influence
of blood product transfusion on morbidity and mortality, in-
traoperative transfusion was associated with a 25% in-
crease in the likelihood of major complications (AOR,
1.25; P< .001) and an 86% increase in the likelihood of
mortality (AOR, 1.86; P<.001). The estimated impact of
postoperative transfusion was even more profound, with
transfusion of blood products associated with 4.5-fold and
4.6-fold increases in the odds of major complications
(AOR, 4.50; P < .001) and mortality (AOR, 4.61;
P<.001) after risk factor adjustment. With respect to the
influence of product transfusion on total costs, HGLM re-
sults demonstrated positive correlations between the trans-
fusion of intraoperative (ß ¼ þ4408, P < .001) and
postoperative (ß ¼ þ10,479, P < .001) blood products
and total hospitalization costs. Thus, the incremental costrdiovascular Surgery c Volume 145, Number 3 799
TABLE 4. Unadjusted patient outcomes by transfusion guideline era
Outcome Pre-guideline era (n ¼ 7059) Post-guideline era (n ¼ 7200) P
Crossclamp time (min)* 65 (50-82) 66 (51-84) <.001
Bypass time (min)* 92 (73-115) 91 (72-115) <.001
Reoperation for bleeding/tamponade 2.1% 1.2% <.001
Stroke 1.3% 1.3% >.99
Perioperative MI 0.2% 0.1% .32
Pneumonia 2.7% 2.0% .01
Prolonged ventilation 4.7% 4.4% .05
Renal failure 3.8% 3.1% .03
Hemodialysis 1.5% 1.0% .004
Major complication 15.1% 13.2% .001
Postoperative ventilation time (h)* 26 (5-16) 22 (5-13) <.001
Operative mortality 1.8% 1.0% <.001
Postoperative LOS (d)* 5 (4-7) 5 (4-7) .97
Median total hospitalization costs ($)* $30,487 (24,516-39,111) $26,197 (21,557-32,752) <.001
Median ICU/CCU costs ($)* $6355 (4033-10,112) $5,710 (3413-8478) <.001
Median respiratory therapy costs ($)* $482 (273-797) $425 (240-730) <.001
MI, Myocardial infarction; LOS, length of stay; ICU, intensive care unit; CCU, critical care unit. *Results reported as median (25th-75th percentile).
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product transfusion after mortality risk adjustment was
$4408, whereas the adjusted incremental cost per hospital-
ization associated with postoperative transfusion of blood
products was $10,479.
The statistical performance of each logistic regression
model achieved good discrimination with an AUC of 0.84
and 0.76 for the operative mortality model and major com-
plications model, respectively. AUC values of 1.0 indicate
perfect model discrimination between dependent outcomes,
and AUC values of 0.5 represent discrimination equal to
chance. The calibration of each model was adequate across
deciles of observed risk as reflected by a Hosmer–
Lemeshow P value less than .05 for both models.
DISCUSSION
The present study reports the successful implementation
of a coordinated, multi-institutional blood conservation ini-
tiative within the Commonwealth of Virginia. In thisTABLE 5. Results of mortality risk-adjusted hierarchic regression
models for effect of operative era and blood product transfusion on
patient outcomes
Factor OR or ß 95% CI P
Operative era
Major complications 0.97 0.88-1.08 .64
Mortality 0.53 0.37-0.74 <.001
Intraoperative transfusion
Major complications 1.25 1.12-1.41 <.001
Mortality 1.86 1.35-2.55 <.001
Total costs ($) þ4408 3337-5480 <.001
Postoperative transfusion
Major complications 4.50 4.03-5.03 <.001
Mortality 4.61 3.19-6.68 <.001
Total costs ($) þ10,479 9581-11,376 <.001
OR, Odds ratio; CI, confidence interval.
800 The Journal of Thoracic and Cardiovascular Surgcontemporary analysis of nonemergency, isolated, primary
CABG outcomes, implementation of transfusion guidelines
resulted in a significant decrease in patient morbidity, mor-
tality, and healthcare costs. Specifically, adoption of trans-
fusion guidelines resulted in decreased intraoperative and
postoperative blood product transfusion rates and a reduc-
tion in the amount of products transfused in both clinical
settings. As a result, patients in the post-guideline era in-
curred important reductions in composite major complica-
tion rates and operative mortality, as well as the accrual of
lower total hospitalization costs. The substantial benefits
derived from the initiation of blood product transfusion
guidelines was even more apparent after mortality risk ad-
justment with an estimated 47% reduction in the odds of
mortality associated with operations performed in the
post-guideline era. These results also quantify the risk-
adjusted impact of intraoperative and postoperative blood
product transfusion on postoperative morbidity and mortal-
ity, demonstrating the significant risk associated with blood
product transfusion in both settings. Unique in the present
findings was the demonstration of the financial implications
associated with blood product transfusion and the signifi-
cant reductions in healthcare costs that could be achieved
through a multi-institutional commitment to transfusion re-
straint. To our knowledge, these data represent the only se-
ries to specifically report on a statewide, multi-institutional
cardiac surgery blood conservation effort to demonstrate
both the clinical and the economic benefits of decreased
blood product use for CABG operations.
A primary objective of the reported initiative was to es-
tablish whether predefined blood conservation guidelines
could be successfully implemented at a multi-institutional
level to effectively reduce intraoperative and postoperative
transfusion rates. The reported results demonstrate that the
blood conservation program was effective in reducingery c March 2013
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Moverall transfusion rates in the post-guideline era among 17
different cardiac centers. These reductions demonstrate that
it is possible to significantly reduce transfusion practices
and rates in cardiac surgery with coordinated, multidisci-
plinary programs that effectively manage permissive ane-
mia in the intraoperative and postoperative settings. The
reported reductions in transfusion rates compare favorably
to other reported single institution series, which further
highlights the success of the coordinated efforts between
multiple institutions in the present results. In one prospec-
tive, randomized trial of patients undergoing CABG, Bra-
cey and colleagues25 reported postoperative transfusion
rates of 20% using a transfusion threshold of hemoglobin
less than 8 g/dL without significant differences in postoper-
ative morbidity or mortality. In 2 other related series,
DeAnda and colleagues26 and Moskowitz and colleagues22
demonstrated substantial reductions in postoperative tra-
nsfusion rates of 16% and 11%, respectively, at single
institutions after implementation of extensive blood conser-
vation programs. Although these series demonstrate excel-
lent success at the single-institution level, these and other
prior published reports have failed to demonstrate that sig-
nificant change in transfusion practices can occur at a larger
statewide or regional level.
The principle findings of reduced morbidity, mortality,
and associated risks resulting from adoption of blood con-
servation guidelines in the present series demonstrate the
safety and efficacy of this multi-institutional approach to
a patient quality initiative and are in agreement with other
published benefits of blood conservation in cardiac surgery.
Instrumental to the initiation and development of an
evidence-based approach to the VCSQI blood conservation
guidelines were the STS and the Society of Cardiovascular
Anesthesiologists clinical practice guidelines for periopera-
tive blood transfusion and conservation in cardiac surgery.27
Moreover, several series have demonstrated similar reduc-
tions in morbidity associated with blood conservation pro-
grams and restrictive transfusion strategies.22,28 Hebert
and colleagues28 reported on the safety of a restrictive trans-
fusion strategy (hemoglobin 7-9 g/dL) compared with a lib-
eral strategy (hemoglobin 10-12 g/dL) in a prospectively
randomized study of 848 patients and demonstrated signif-
icant differences in mortality between study groups. An-
other recent study of 2 propensity-matched study cohorts
of 586 patients reported that a blood conservation program
resulted in significantly lower serious (11%) and very seri-
ous complications (10.6%) after CABG.22 In this series, the
13% major complication rate reported among patients in
the post-guideline era coupled with the 1% mortality rate
for this cohort is consistent with these reports and supports
a restrictive transfusion strategy. More important, the bene-
fits of restrictive transfusion guidelines were even more ap-
parent after mortality and hospital risk adjustment. After
mortality risk adjustment, patients undergoing operationsThe Journal of Thoracic and Casince the introduction of transfusion guidelines were associ-
ated with a 47% reduced likelihood of death compared with
patients undergoing the same operations before established
guidelines. Coupled with the aforementioned reductions in
observed morbidity, these results provide an important
foundation from which future randomized controlled trials
using these transfusion guideline triggers can be designed.
Transfusion of both intraoperative and postoperative
blood products was significantly associated with increased
mortality and morbidity in this series regardless of blood
conservation strategy or guideline implementation. On
hierarchic logistic regression modeling, intraoperative
transfusion was associated with a 25% increase in the
odds of composite major complications (AOR, 1.25;
P< .001) and an 86% increase in the odds of mortality
(AOR, 1.86; P<.001). Even more striking was that postop-
erative transfusion was associated with a 4.5-fold increase
(P< .001) in the odds of composite major complications
and a 4.6-fold increase (P<.001) in mortality. It is possible
that the influence of significant postoperative bleeding may
have affected these estimated effects; however, because of
the relatively small proportion of patients undergoing reop-
erations for bleeding/tamponade (<2% overall), we believe
this influence to be small. Nevertheless, the observed associ-
ations between transfusions and patient morbidity and mor-
tality in this series arewell corroborated in other reports.7,9-12
Koch and colleagues9 reported on more than 10,000 patients
undergoing CABG and demonstrated that transfusion was
associated with reduced short- and long-term risk-adjusted
survival. Likewise, Whitson and colleagues29 identified
transfusion as an independent risk factor for increased mor-
bidity and mortality among patients undergoing cardiac sur-
gery.Moreover, Surgenor and coauthors12 demonstrated that
exposure to 1 or 2 units of transfused PRBC was associated
with a 16% hazard of decreased survival in a multi-
institutional cohort of more than 9000 patients. Thus, the
present results serve to bolster those of previous reports to
further advocate for coordinated blood conservation pro-
grams to further reduce cardiac surgical risk and morbidity.
A unique aspect of this report are the findings of signifi-
cant cost reductions that occurred with the successful
implementation of a blood conservation initiative. The
striking findings that total hospitalization costs were re-
duced by $49 million dollars statewide over a 2-year study
period with a median reduction of $4000 per patient hospi-
talization after the introduction of the blood conservation
guidelines demonstrate the important financial implications
that coordinated quality efforts can achieve. Moreover, the
financial impact of blood product transfusion and the re-
ported $4408 and $10,479 adjusted incremental costs of
hospitalization associated with intraoperative and postoper-
ative transfusion, respectively, are in agreement with other
reported cost analyses. In a report examining the financial
impact of blood product transfusions on hospital costsrdiovascular Surgery c Volume 145, Number 3 801
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reported that the incremental cost per hospitalization asso-
ciated with bleeding-related complications or transfusions
was $10,279 among a total of 103,829 patients undergoing
cardiac surgery. The authors noted similar associations
between blood transfusion and hospitalization costs for
vascular and noncardiac thoracic surgical populations.30
The reported results have important clinical implications.
In an era of increasingly complex operations and patients,
these results provide clinical estimates of the adjusted im-
pact of blood conservation guidelines on the performance
of CABG operations. Moreover, these results represent
a large, multi-institutional cohort of patients, providing a re-
port of outcomes that are more generalizable than those of
other small, single-institutional series. The use of multilevel
structured multivariable regression models with strong per-
formance indices demonstrates that the granularity of the
analyzed data is appropriately controlled for in the reported
statistical associations. Most important, these results high-
light the importance of cooperative regional efforts in the
recognition of important quality-improvement opportuni-
ties and guideline development to derive both clinical and
financial benefits for patients undergoing cardiac surgery.
Study Limitations
The present study has limitations. First, the secondary
analysis of the VCSQI data registry and STS data limited
the performed analyses to deidentified data, which did not
allow for further investigation of certain data, including de-
tails related to postoperative bleeding episodes, nature of
stored blood products, or use of red blood cell salvage. In
fact, the influence of red blood cell storage duration has be-
come increasingly emphasized and is the focus of the ongo-
ing large multicenter RECESS trial supported by the
National Institutes of Health. The retrospective study design
is subject to limitations of inherent selection bias, and the
reported results are limited to describe observed associa-
tions between the implementation of the described protocol
and the improved patient outcomes and do not demonstrate
a direct cause-and-effect relationship. Differences in adher-
ence rates among participating centers to blood conserva-
tion guidelines and differences in physician behavior on
transfusion practices could exert unmeasured influences in
these analyses. Despite consensus agreement on guidelines,
individual centers and physicians were responsible to en-
force guideline practices, and the influence of less adherent
centers or physicians would have biased the results toward
the null hypothesis. Nevertheless, the reported results were
adjusted for the confounding influence of center and physi-
cian differences; however, despite these efforts, the influ-
ence of physician behavior that has occurred over the
study period cannot be completely accounted for in the re-
ported results. Thus, the reported results have the potential
to underestimate additional benefits that could be achieved802 The Journal of Thoracic and Cardiovascular Surgwith expanded implementation. The influence of differ-
ences in postoperative critical care management between
institutions also cannot be fully accounted for in these anal-
yses; however, the hierarchic structure of the performed re-
gression analyses likely mitigated this influence because it
was designed to account for variance in correlated events
between hospitals. All analyses were limited to short-term
operative outcomes, and intermediate or long-term fol-
low-up data were not available. Finally, the potential for un-
recognized miscoding of data must be considered in any
secondary analysis of a data registry.CONCLUSIONS
The results of the present study demonstrate that imple-
mentation of a coordinated blood use initiative at a statewide
level can significantly improve postoperative morbidity,
mortality, and resource use among patients undergoing
CABG operations. Limiting intraoperative and postopera-
tive blood product transfusion decreases adverse postoper-
ative events and reduces hospitalization-related costs.
These results argue for increased blood conservation efforts
bolstered by collaboration and guideline development.
The authors thank George J. Stukenborg, PhD, for statistical
mentorship in this study.References
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Dr Edward Verrier (Seattle, Wash). Drs Lazar, McGiffin, and
LaPar, thank you for the opportunity to discuss this well-presented
analysis of outcomes and costs after the implementation of a mul-
tidisciplinary blood conservation program incorporating 14,000
patients in 17 different cardiac surgery programs in the Common-
wealth of Virginia. The Virginia Cardiac Surgery Quality Initiative
should be commended for their organization, structure, database,
and priorities.The Journal of Thoracic and CaThe study looks at nonemergent isolated CABG patients over 2
time periods—2006 to 2008 and 2008 through 2010. Strict blood
transfusion triggers were implemented intraoperatively and in
the surgical intensive care unit, and looked at short-term outcome
variables and detailed analysis of costs with the introduction of
such a blood conservation program.
The conclusions of improved outcomes are not new as carefully
pointed out in the manuscript. The details of the cost improvement
with such a program are the most significant contribution of this
effort. In addition, the scope of involvement over an entire state re-
veals the accomplishments that can be achieved with excellent
organization, priority, commitment, and leadership.
Dr Bruce Spiess, one of the authors of this effort, and I shared
similar improvements in outcomes with the initiation of such
a blood conservation program at the University of Washington
more than 20 years ago, and we strictly follow that transfusion pro-
tocol today.
The authors note the limitations of the study in this manuscript.
The study is retrospective, spans 2 sequential time periods, does
not account for improvements in blood banking or critical care ser-
vices, miscoding, and certainly could be influenced by increased
awareness and better discipline by the entire surgical, anesthesia,
perfusion, and critical care teams.
My first question relates to cause and effect. Did the authors
carefully look through the STS database over the same time period
to see if improvements in outcomes for isolated elective 2-vessel
CABG also improved nationally in the large database in programs
without the initiation of such a blood transfusion conservation pro-
tocol? I suspect a modest improvement in outcomes noted by the
authors might also have been seen over that time frame, as
reflected in that large database.
Dr LaPar. Thank you very much for your question, and I think
that you bring up some very important points, the first being that
when we are comparing data within a region or state, it is very im-
portant to compare that data with national trends and outcomes.
Nationally, we have seen CABG outcomes improve over time,
and certainly these trends and the influence of a time bias, for
example, may influence to a small extent the results of this study.
In these analyses, we did not include a subanalysis of CABG
outcomes by individual center or program to further determine
the effect of improving CABG outcomes over time. This is an
interesting point and one that deserves further investigation.
Dr Verrier.My second question relates to the question of trans-
fusion as a marker of injury versus transfusion as an immunomod-
ulator. It is similar to the discussion of acute renal failure in
outcomes.We know that patients with acute renal failure doworse,
and the question is, is that because they have acute renal failure, or
is the renal failure a reflection of the complexity of the disease?
I realize this study was risk adjusted, but in every discussion in
the cardiothoracic literature or trauma literature, the question of
whether transfusion is a double-edged sword that we have come
to understand, is that true or not? Did the authors get any signifi-
cant scientific insight related to cytokine production, viral vectors,
or immunologic mediators that caused this adverse effect on out-
comes such as transfusion-related pulmonary toxicity or acute
tubular necrosis?
Dr LaPar.Unfortunately, because of the de-identified nature of
the VSCQI data registry, we were confined in these analyses tordiovascular Surgery c Volume 145, Number 3 803
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though I agree that the systemic and inflammatory markers you
mentioned may, in fact, provide further information on the effects
and or benefits of blood product use or conservation, we were un-
able to analyze such data. Rather, we are able to gain some insight
into these effects in our comparison of the clinical manifestations
of these processes such as the incidence of renal insufficiency or
prolonged mechanical ventilation as we have in our analysis.
These differences remain hypothesis generating though, and I
agree that it would be interesting to further investigate such effects
of immunomodulation at the single institution level. This is a ques-
tion that we will take back to our institution to look at in the future.
Dr Verrier. I certainly enjoyed the opportunity to hear this
excellent presentation and believe this will be an important contri-
bution to our literature. I hope that it is now extended, based on this
experience at the statewide level, to the national level because
the implications there at the national level, both on the cost anal-
ysis and outcomes, would be significant. Thank you for the
opportunity.
Dr LaPar. Thank you.
Dr David McGiffin (Birmingham, Ala). I do not want to take
anything away from your study, because I agree with your conclu-
sions, but I just wanted to make an observation that when I look at
that table of the number of outcomes from the preguideline to the
postguideline eras, the differences are very, very small—for exam-
ple, prolonged ventilation, 4.7% to 4.4%. And we have to be care-
ful we that we do not overemphasize the very small differences that
may be statistically significant but of very questionable biologic
importance, because there is no difference that is not small enough
that we cannot transform into a significant P value by having
sufficient numbers.
Dr LaPar. Certainly the effect of a large sample size, as in our
study, allows small differences to achieve statistical significance.
However, some of the most significant limitations of former series
evaluating the effects of blood product use in cardiac surgery are
the inclusion of smaller patient samples from single institutions
that limits the statistical power of their analyses and the generaliz-
ability of their results. Our study addresses these concerns with
a large, multi-institutional cohort of patients and outcomes.
Dr Paul Kurlansky (Miami, Fla). I would like to expand on the
first point that Dr Verrier brought up, which is the effect of time on
behavior. Virginia has done a magnificent job in bringing people
together and trying to work together on quality initiatives. How-
ever, as I understand it, there is tremendous variability on the ac-
tual application or implementation of various guidelines that are
recommended by the collaborative. I was wondering if you have
any mechanism to track the compliance with the guidelines
amongst the various 17 different centers and whether compliance804 The Journal of Thoracic and Cardiovascular Surgwas in any way associated with outcome as a way to guard against
the post hoc ergo propter hoc influence of time?
Dr LaPar. That is a great point, and I think it is important to
recognize that in this study therewas some variability between par-
ticipating centers in the enforcement of the blood transfusion
guidelines once they were agreed upon. With respect to our anal-
yses, the effect of this variability would likely bias the results
toward the null. To date, our organization has not implemented
a particular mechanism to track center compliance. Such a process
would be helpful, however, and is something we can discuss for
future comparisons.
As you mentioned, one of the greatest strengths of this study is
that it shows the ability to organize a group of centers, bring them
together to develop a group of guidelines, and to implement the
guidelines to achieve not only improved clinical outcomes but
also financial benefits as well. And our demonstration of a $49mil-
lion reduction in overall total hospitalization costs during a 2-year
period in the Commonwealth of Virginia is extremely important. It
would be great if we could capture the financial benefits of such an
initiative at the nationwide level.
More importantly, we would like to emphasize that we do know
that within hospitals that did very well with the guideline compli-
ance that these hospitals actively involved the individual caregiver
responsible for carrying out the guideline specifics. These individ-
uals included cardiac surgical trainees and fellows, nurse practi-
tioners, or physicians assistants, depending on the center. To be
successful, it is important to involve these individual early in the
implementation of the guidelines and then provide them consistent
and frequent feedback on impact of the initiative. When this hap-
pens, it serves to reinforce guideline compliance.
Dr Harold Lazar (Boston, Mass). Can you tell us what the dif-
ference was in the incidence of the use of Plavix between the
groups? And also can you tell us a little bit about the cardiopulmo-
nary bypass techniques? Did they use heparin-bonded circuits?
Was miniature circuitry used? Can you tell us anything about those
techniques between the time periods?
Dr LaPar. In our patient cohort, the use of Plavix was higher in
the postguideline era compared with the preguidelines era. And, I
am sorry, I could not exactly hear your question related to cardio-
pulmonary bypass.
Dr Lazar. The techniques of cardiopulmonary bypass, whether
or not you used heparin-bonded circuitry, whether you used cardi-
otomies for your pumps.
Dr LaPar. Those are important factors, and we did not have that
data available to analyze. The impact of these techniques would
certainly be something that we can look at in the future as this is
an area of research that we want to continue to investigate within
our organization.ery c March 2013
